These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16189112)

  • 1. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
    Mo H; Lu L; Pilot-Matias T; Pithawalla R; Mondal R; Masse S; Dekhtyar T; Ng T; Koev G; Stoll V; Stewart KD; Pratt J; Donner P; Rockway T; Maring C; Molla A
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4305-14. PubMed ID: 16189112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
    Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
    Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
    Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
    Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
    Howe AY; Cheng H; Thompson I; Chunduru SK; Herrmann S; O'Connell J; Agarwal A; Chopra R; Del Vecchio AM
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4103-13. PubMed ID: 16940072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
    Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
    J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
    Delang L; Froeyen M; Herdewijn P; Neyts J
    Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
    Lu L; Mo H; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1889-96. PubMed ID: 17371824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
    Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.
    Tomei L; Altamura S; Bartholomew L; Bisbocci M; Bailey C; Bosserman M; Cellucci A; Forte E; Incitti I; Orsatti L; Koch U; De Francesco R; Olsen DB; Carroll SS; Migliaccio G
    J Virol; 2004 Jan; 78(2):938-46. PubMed ID: 14694125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
    Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
    Lin C; Lin K; Luong YP; Rao BG; Wei YY; Brennan DL; Fulghum JR; Hsiao HM; Ma S; Maxwell JP; Cottrell KM; Perni RB; Gates CA; Kwong AD
    J Biol Chem; 2004 Apr; 279(17):17508-14. PubMed ID: 14766754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
    Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
    Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor.
    Nguyen TT; Gates AT; Gutshall LL; Johnston VK; Gu B; Duffy KJ; Sarisky RT
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3525-30. PubMed ID: 14576112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.